Coronavirus and the safety of immunoglobulin products

The Plasma Protein Therapeutics Association (PPTA) has issued a statement (dated 29th January 2020) saying that the virus is not a concern for the safety of plasma protein therapies, including immunoglobulin, manufactured by PPTA member companies (this covers all UK suppliers). 

The PPTA states that ‘Based on strict screening procedures for plasma donors and the established processes of virus inactivation and removal during manufacturing of plasma-derived products, PPTA concludes that the 2019 Novel Coronavirus (2019-nCoV) is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies’.

You can read the rationale and full statement at
https://www.pptaglobal.org/media-and-information/ppta-statements/1055